drugset
drugset / Trial / NCT01654549

Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis

NCT01654549 ↗

Phase 2 Completed 40 enrolled Tehran University of Medical Sciences
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of study was to evaluate the effect of helicobacter pylori eradication on liver fat content, liver function tests, lipid profile, homeostasis model assessment-IR (HOMA-IR) index, and anthropometric measurements (body mass index and waist circumference)in non-diabetic subjects with non-alcoholic fatty liver disease.

Timeline

Start
2012-04
Primary completion
2012-09
Completion
2012-09

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Liver Fat Content Change in H.Pylori Eradication vs Liver Fat Content Change in Lifestyle Modification; p = 0.10; t-test, 2 sided NCT01654549 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 1 g —
Subject Azithromycin Small molecule 500 mg —
Subject Bismuth subcitrate Unknown 240 mg —
Subject Omeprazole Other / unclassified 20 mg —

Indications

NAFLD1